Subscribe to Newsletter
Subspecialties Glaucoma, Basic & Translational Research

Easy Does It?

When it comes to ocular hypertension, conventional wisdom points to the need to act fast to protect vision. But recent findings suggest otherwise. The Ocular Hypertension Treatment Study (funded by the National Eye Institute and led by researchers at Washington University School of Medicine, USA) recruited 1,600 patients who were at moderate to high risk for glaucoma because of elevated eye pressure. Half received daily treatment with eye drops, while the other half were observed without treatment. After seven years, when the treatment had been shown to be highly effective, patients in both groups were given drops. The team showed that preventive treatment reduced the incidence of glaucoma by 50 to 60 percent after five to seven years, but even with that substantial decrease, the total number of people who developed glaucoma remained relatively low, with only 25 percent going on to develop vision loss from glaucoma in at least one eye – much fewer than initially expected.

Physicians can delay pressure-lowering treatment [...] without adversely affecting long-term outcomes.

The study suggests physicians can delay pressure-lowering treatment until early damage is detected, without adversely affecting long-term outcomes. The next step? Determining which patients would benefit from preventative treatment.

Michael A. Kass, the Bernard Becker Professor of Ophthalmology and Visual Sciences and lead author of the study, helped establish the five key risk factors: a patient’s age, level of intraocular pressure, thickness of the cornea, a measurement of the appearance of the optic nerve head, and another measurement derived from standard visual field tests. “The five factors were determined using a multivariable risk model where they were entered one at a time to see if they improved the predictive power, with all factors weighted to one standard deviation,” explains Kass.

While Kass does not consider a delay in pressure-lowering treatment risky, a high-risk person or a person who is concerned can start treatment before damage is detected. “This should cause the clinician and the patient to discuss the situation taking into consideration patient age, health status, life expectancy and personal preference.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. WUSTL (2021). Available at:
About the Author
Phoebe Harkin

Associate Editor of The Ophthalmologist

I’ve always loved telling stories. So much so, I decided to make a job of it. I finished a Masters in Magazine Journalism and spent three years working as a creative copywriter before itchy feet sent me (back)packing. It took seven months and 13 countries, but I’m now happily settled on The Ophthalmologist, where I’m busy getting stuck into all things eyeballs.

Related Case Studies
Business & Profession Glaucoma
TrabEx Pro: The Next Level in MIGS

| Contributed by MST

Finding Ocular Surface Inflammation

| Contributed by Quidel

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: